276 related articles for article (PubMed ID: 21488592)
1. Drospirenone: high risk of venous thrombosis.
Prescrire Int; 2011 Feb; 20(113):43-5. PubMed ID: 21488592
[TBL] [Abstract][Full Text] [Related]
2. Risk of thromboembolism in women taking ethinylestradiol/drospirenone and other oral contraceptives.
Seeger JD; Loughlin J; Eng PM; Clifford CR; Cutone J; Walker AM
Obstet Gynecol; 2007 Sep; 110(3):587-93. PubMed ID: 17766604
[TBL] [Abstract][Full Text] [Related]
3. Combined oral contraceptives: venous thrombosis.
de Bastos M; Stegeman BH; Rosendaal FR; Van Hylckama Vlieg A; Helmerhorst FM; Stijnen T; Dekkers OM
Cochrane Database Syst Rev; 2014 Mar; 2014(3):CD010813. PubMed ID: 24590565
[TBL] [Abstract][Full Text] [Related]
4. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
Cianci A; De Leo V
Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
[TBL] [Abstract][Full Text] [Related]
5. Drospirenone: more cases of thrombosis than with levonorgestrel.
Prescrire Int; 2013 Nov; 22(143):267. PubMed ID: 24427839
[TBL] [Abstract][Full Text] [Related]
6. Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis.
Stegeman BH; de Bastos M; Rosendaal FR; van Hylckama Vlieg A; Helmerhorst FM; Stijnen T; Dekkers OM
BMJ; 2013 Sep; 347():f5298. PubMed ID: 24030561
[TBL] [Abstract][Full Text] [Related]
7. A study of cycle control, side effects and client's satisfaction of a low dose combined contraceptive containing ethinylestradiol/drospirenone (24/4 regimen).
Chaiyasit N; Taneepanichskul S
J Med Assoc Thai; 2010 May; 93(5):517-22. PubMed ID: 20524436
[TBL] [Abstract][Full Text] [Related]
8. The truth about oral contraceptives and venous thromboembolism.
Shulman LP; Goldzieher JW
J Reprod Med; 2003 Nov; 48(11 Suppl):930-8. PubMed ID: 14686030
[TBL] [Abstract][Full Text] [Related]
9. Effect of an oral contraceptive containing drospirenone on the renin-angiotensin-aldosterone system in healthy female volunteers.
Oelkers W; Helmerhorst FM; Wuttke W; Heithecker R
Gynecol Endocrinol; 2000 Jun; 14(3):204-13. PubMed ID: 10923282
[TBL] [Abstract][Full Text] [Related]
10. Effect of a combination of ethinylestradiol 30 microg and drospirenone 3 mg on tolerance, cycle control, general well-being and fluid-related symptoms in women with premenstrual disorders requesting contraception.
Borges LE; Andrade RP; Aldrighi JM; Guazelli C; Yazlle ME; Isaia CF; Petracco A; Peixoto FC; Camargos AF
Contraception; 2006 Dec; 74(6):446-50. PubMed ID: 17157100
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy and safety of drospirenone-ethinylestradiol on contraception in healthy Chinese women: a multicenter randomized controlled trial].
Fan GS; Bian ML; Cheng LN; Cao XM; Huang ZR; Han ZY; Jing XP; Li J; Wu SY; Xiong CL; Xiong ZA; Yue TF
Zhonghua Fu Chan Ke Za Zhi; 2009 Jan; 44(1):38-44. PubMed ID: 19563061
[TBL] [Abstract][Full Text] [Related]
12. Yasmin: the reason why.
Thorneycroft IH
Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 3():13-8; discussion 42-3. PubMed ID: 12659402
[TBL] [Abstract][Full Text] [Related]
13. Effects of second and third generation oral contraceptives and their respective progestagens on the coagulation system in the absence or presence of the factor V Leiden mutation.
Kemmeren JM; Algra A; Meijers JC; Bouma BN; Grobbee DE
Thromb Haemost; 2002 Feb; 87(2):199-205. PubMed ID: 11859850
[TBL] [Abstract][Full Text] [Related]
14. Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or desogestrel compared with oral contraceptives containing levonorgestrel.
Jick SS; Kaye JA; Russmann S; Jick H
Contraception; 2006 Jun; 73(6):566-70. PubMed ID: 16730485
[TBL] [Abstract][Full Text] [Related]
15. Risk of venous thromboembolism with drospirenone in combined oral contraceptive products.
Sehovic N; Smith KP
Ann Pharmacother; 2010 May; 44(5):898-903. PubMed ID: 20371756
[TBL] [Abstract][Full Text] [Related]
16. Higher risk of venous thrombosis associated with drospirenone-containing oral contraceptives: a population-based cohort study.
Gronich N; Lavi I; Rennert G
CMAJ; 2011 Dec; 183(18):E1319-25. PubMed ID: 22065352
[TBL] [Abstract][Full Text] [Related]
17. Ethinylestradiol + norelgestromin: new preparation. Transdermal contraception: no tangible progress.
Prescrire Int; 2004 Aug; 13(72):123-6. PubMed ID: 15532134
[TBL] [Abstract][Full Text] [Related]
18. A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways.
Tans G; Curvers J; Middeldorp S; Thomassen MC; Meijers JC; Prins MH; Bouma BN; Büller HR; Rosing J
Thromb Haemost; 2000 Jul; 84(1):15-21. PubMed ID: 10928463
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular risks associated with the use of drospirenone-containing combined oral contraceptives.
Dinger J; Möhner S; Heinemann K
Contraception; 2016 May; 93(5):378-85. PubMed ID: 26825258
[TBL] [Abstract][Full Text] [Related]
20. Serum potassium monitoring for users of ethinyl estradiol/drospirenone taking medications predisposing to hyperkalemia: physician compliance and survey of knowledge and attitudes.
Mona Eng P; Seeger JD; Loughlin J; Oh K; Walker AM
Contraception; 2007 Feb; 75(2):101-7. PubMed ID: 17241838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]